two

two Earnings Recaps

BFLY Financials 3 recaps
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Oct 30, 2026

Butterfly shares fell 3.8% after earnings, despite a revenue beat and higher full-year guidance. The likely pressure point was continued international softness: management said it persisted this quarter after deal-timing shifts, and its expected improvement is pushed to Q4 and 2027.

Key takeaways
  • Q3 revenue was $32.6 million, 9% above the top end of guidance; management raised full-year guidance on both the top and bottom lines.
  • U.S. HHS revenue grew 15%. The quarter included five seven-figure and ten six-figure enterprise deals measured by total contract value.
  • International POCUS remained soft for a second quarter. Butterfly plans to shift toward larger institutional and enterprise customers and expects improvement in Q4 and into 2027.
  • Management reported the highest gross margin in company history, but the transcript provides no margin figure.
  • Butterfly secured FedRAMP authorization and signed five new Garden partners; DeepEcho also launched the first international Garden application.
Q2 2026 Aug 1, 2026

Butterfly Network's stock was largely unchanged following Q2 2026 results, reflecting a balanced mix of steady execution in Embedded partnerships and gradual software adoption without clear upside surprises.

Key takeaways
  • Revenue, gross margins, and adjusted EBITDA came in near the top of prior guidance; full year guidance was raised modestly.
  • Embedded partnerships reached a total of 11 with two new agreements, broadening applications in brain-computer interfaces and women's health wearables.
  • Point-of-care ultrasound (POCUS) business advanced with six new enterprise software deals for Compass AI, growing the pipeline fivefold since last year.
  • Provisional authorization secured to sell to the entire VA system; broader U.S. government sales opportunities are developing.
  • Despite management’s positive framing, the market viewed progress as incremental rather than breakthrough, leading to a flat share price reaction of +0.1%.
Q1 2026 May 1, 2026

Butterfly Network shares surged 9.8% following Q1 2026 earnings as investors responded positively to 25% revenue growth, expanding gross margin, and clear progress in enterprise AI-driven adoption. Acceleration in software deals and FDA recognition of new AI tools contributed to the upbeat market reaction.

Key takeaways
  • Reported 25% year-over-year revenue growth for the first quarter.
  • Gross margin reached 69%, with net loss at its lowest Q1 level since the company went public.
  • Achieved FDA clearance for a blind sweep AI tool to determine fetal gestational age, positioned for a U.S. and global rollout.
  • Two new partners joined the Butterfly Garden ecosystem, with four partner apps receiving FDA clearance and additional breakthrough designations.
  • Pipeline of software deals, measured by total contract value, rose sharply year-on-year, including a 7-figure Compass AI enterprise agreement and nearly 1,000 probes sold to medical schools in early 2026.